References
- Shen C, Wang Z, Fang Z, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582–9.
- Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20:398–400.
- Rodriguez Z, Shane AL, Verkerke H, et al. COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease. Blood Adv 2020;4:4278–81.
- Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest 2020;130:4791–7.
- Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest 2020;158:e9–e13.
- Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from COVID-19. N Engl J Med. 13 January 2021 [Epub ahead of print]. DOI: 10.1056/NEJMoa2031893. Available from https://pubmed.ncbi.nlm.nih.gov/33523609/. Accessed January 2021.
- Libster R, Marc GP, Wappner D, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med 2021;384:610–8.
- Stowell SR, Guarner J. Role of serology in the coronavirus disease 2019 pandemic. Clin Infect Dis 2020;71:1935–6.
- den Hartog G, Schepp RM, Kuijer M, et al. SARS-CoV-2-specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence. J Infect Dis 2020;222:1452–61.
- Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581:215–20.
- Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 2020;368:630–3.
- Verkerke H, Horwath M, Saeedi B, et al. Comparison of antibody class specific SARS-CoV-2 serology for the diagnosis of acute COVID-19. J Clin Microbiol. 10 January 2021 [Epub ahead of print]. DOI: 10.1128/JCM.02026-20. Available from https://pubmed.ncbi.nlm.nih.gov/33468605/. Accessed January 2021.
- Allen JWL, Verkerke H, Owens J, et al. Serum pooling for rapid expansion of anti-SARS-CoV-2 antibody testing capacity. Transfus Clin Biol 2021;28:51–4.
- Suthar MS, Zimmerman MG, Kauffman RC, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med 2020;1:100040.
- Luchsinger LL, Ransegnola B, Jin D, et al. Serological analysis of New York City COVID19 convalescent plasma donors. medRxiv 2020 June 9;2020.06.08.20124792.
- Corthesy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol 2013;4:185.
- Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998;221: 35–41.
- Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol 2016;5:85–6.
- Spackman E, Malladi S, Ssematimba A, Stephens CB. Assessment of replicate numbers for titrating avian influenza virus using dose-response models. J Vet Diagn Invest 2019;31:616–9.
- Stowe RP, Ruiz RJ, Fagundes CP, Stowe RH, Chen M, Glaser R. An ELISA method to compute endpoint titers to Epstein-Barr virus and cytomegalovirus: application to population-based studies. J Immunol Methods 2014;408:64–9.
- Balingit JC, Ly MHP, Matsuda M, et al. A simple and high-throughput ELISA-based neutralization assay for the determination of anti-flavivirus neutralizing antibodies. Vaccines (Basel) 2020;8:297.
- Pujadas E, Ibeh N, Hernandez MM, et al. Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test. J Med Virol 2020;92: 1695–8.
- Xu P, Sun GD, Li ZZ. Clinical characteristics of two human-to-human transmitted coronaviruses: corona virus disease 2019 vs. Middle East respiratory syndrome coronavirus. Eur Rev Med Pharmacol Sci 2020;24:5797–809.
- Huang JL, Lin HT, Wang YM, et al. Rapid and sensitive detection of multiple genes from the SARS-coronavirus using quantitative RT-PCR with dual systems. J Med Virol 2005;77:151–8.
- GraphPad Prism 8. 2020. Available from https://www.graphpad.com/scientific-software/prism/. Accessed 2020.
- Kohn LT, Corrigan JM, Donaldson MS, Eds. To Err is Human: Building a Safer Health System. Washington, DC: National Academic Press, 2000.
- Python 3.0 Release. 2020. Available from https://www.python.org/download/releases/3.0. Accessed 2020.
- Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020;323:1561–2.
- Gharbharan A, Jordans CCE, Geurtsvankessel C, et al. Convalescent plasma for COVID-19; A randomized clinical trial. medRxiv 2020.07.01.20139857.
- Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371:m3939.
- Eckhardt CM, Cummings MJ, Rajagopalan KN, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials 2020;21:499.
- Zerra PE, Cox C, Baldwin WH, et al. Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A. Blood 2017;130:2559–68.
- Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Hematology Am Soc Hematol Educ Program 2014;2014:364–71.
- Strandenes G, Berséus O, Cap AP, et al. Low titer group O whole blood in emergency situations. Shock 2014;41(Suppl 1):70–5.
- Stowell SR, Stowell CP. Biologic roles of the ABH and Lewis histo-blood group antigens part II: thrombosis, cardiovascular disease and metabolism. Vox Sang 2019;114:426–42.
- Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130:2757–65.
- Denomme GA, Anani WQ. ABO titers: harmonization and identifying clinically relevant ABO antibodies. Transfusion 2020;60:441–3.
- Adcock DM, Favaloro EJ. Pearls and pitfalls in factor inhibitor assays. Int J Lab Hematol 2015;37(Suppl 1):52–60.
- Katz LM. (A little) clarity on convalescent plasma for Covid-19. N Engl J Med 2021;384:666–8.
- Verkerke HP, Maier CL. Towards characterized convalescent plasma for COVID-19: the dose matters. EClinicalMedicine 2020;26:100545.
- Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 2021;184:476–488.e11.
- Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324:460–70.
- Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693–704.
- Woodruff MC, Ramonell RP, Lee FE, Sanz I. Broadly-targeted autoreactivity is common in severe SARS-CoV-2 infection. medRxiv 2020 Oct 23;2020.10.21.20216192.
- Devreese KMJ, Linskens EA, Benoi D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost 2020;18:2191–2201.
- Khamsi R. Rogue antibodies could be driving severe COVID-19. Nature 2021;590:29–31.
- Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014;371:1381–91.
- Sparger KA, Assmann SF, Granger S, et al. Platelet transfusion practices among very-low-birth-weight infants. JAMA Pediatr 2016;170:687–94.
- Curley A, Stanworth SJ, Willoughby K, et al. Randomized trial of platelet-transfusion thresholds in neonates. N Engl J Med 2019;380:242–51.
- Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020;4:327–55.
- Thein SL, Pirenne F, Fasano RM, et al. Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica 2020;105:539–44.
- Cohn CS. Platelet transfusion refractoriness: how do I diagnose and manage? Hematology Am Soc Hematol Educ Program 2020;2020:527–32.
- Arthur CM, Patel SR, Sullivan HC, et al. CD8+ T cells mediate antibody-independent platelet clearance in mice. Blood 2016;127:1823–7.
- Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv 2020 Aug 12;2020.08.12.20169359.
- Ezzelle J, Rodriguez-Chavez IR, Darden JM, et al. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J Pharm Biomed Anal 2008;46:18–29.
- Kubina R, Dziedzic A. Molecular and serological tests for COVID-19: a comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. Diagnostics (Basel) 2020;10:434.
- Lisboa Bastos M, Tavaziva G, Kunal Abidi S, et al. Diagnostic accuracy of serological tests for COVID-19: systematic review and meta-analysis. BMJ 2020;370:m2516.